Mallinckrodt and Respironics settle old score:
This article was originally published in Clinica
Mallinckrodt and Respironics have reached agreement to settle litigation begun by companies which they acquired. Nellcor Puritan Bennett, now part of Mallinckrodt was suing Healthdyne Technologies, subsequently taken over by Pittsburgh-based Respironics, over trade secrets concerning Nellcor's liquid oxygen business. Also named in the suit were Trent Products and a former Nellcor general manager, Jay Hayes, who is now employed by Respironics. Financial terms of the settlement were not revealed, but Respironics will pay royalties for proprietary technology from Mallinckrodt's Nellcor division.
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.